959119-78-9

Basic information

• Product Name: 4-(2-(tosyloxy)acetamido)benzoic acid
• CAS NO: 959119-78-9
• Molecular Weight: 349.364
• Mol File: 959119-78-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 4-(2-(tosyloxy)acetamido)benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-(tosyloxy)acetamido)benzoic acid(959119-78-9)
• EPA Substance Registry System: 4-(2-(tosyloxy)acetamido)benzoic acid(959119-78-9)

Safety Data

• Hazardous Substances Data: 959119-78-9(Hazardous Substances Data)

Upstream product

• 98-59-9 p-toluenesulfonyl chloride 
• 39794-77-9 2-(4-methylphenyl)sulfonyloxyacetic acid 
• 39794-75-7 ethyl α-p-toluenesulfonyloxyacetate 

Relevant articles and documents

SMALL MOLECULE INHIBITORS OF STAT3 WITH ANTI-TUMOR ACTIVITY

The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of Stat3 signaling, Stat3 dimerization, Stat3-DNA binding, Stat5-DNA binding, and/or aberrant cell growthinvitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, NSC 74859 (S3I-201), NSC 42067, NSC 59263, NSC 75912, NSC 11421, NSC 91529, NSC 263435, and pharmaceutically acceptable salts and analogs of the foregoing. Other non-malignant diseases characterized by proliferation of cells that may be treated using the compounds of the invention, but are not limited to, cirrhosis of the liver; graft rejection; restenosis; and disorders characterized by a proliferation of T cells such as autoimmune diseases, e.g., type 1 diabetes, lupus and multiple sclerosis. The invention further includes an in-vitro screening test for the presence of malignant cells in a mammalian tissue; a method of identifying inhibitors of constitutive Stat3 activation, Stat3-DNA binding, Stat5-DNA binding, and/or Stat3 dimerization; and a method of identifying anti-cancer agents.